ArticleClinical rheumatology2025
Antinuclear antibodies as a risk factor for ischemic stroke or death in elderly patients with atrial fibrillation despite anticoagulation.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveAntinuclear antibodies (ANA) at low titers of 1:40 may be present in up to 30% of healthy individuals and have been associated with increased cardiovascular mortality, but their role in atrial fibrillation (AF) remains unclear. This study assessed ANA prevalence and its association with outcomes in AF patients.
methodsIn a cohort of 240 AF patients on anticoagulant therapy (median age 69, median CHA2DS2-VASc = 4), without any ANA-related autoimmune diseases, we determined ANA (positive if > 20 ELISA units [EU]) along with antiphospholipid antibodies in accordance to ACR/EULAR (ACR/EULAR-aPL). During a median follow-up of 52 months, ischemic stroke (IS), transient ischemic attack (TIA), cardiovascular (CV) death, major bleeding, and a composite endpoint (defined as IS, TIA, or CV death) were recorded.
results43 patients (17.9%) were positive for ANA (mean 22.9 EU), including 20 (46.5%) with positive ACR/EULAR-aPL. ANA-positive patients were older (by 9.9 years), predominantly female (65.1%), and had higher CHA2DS2-VASc scores (median 5 vs 4; all P < 0.001). IS or CV death occurred in 30 patients (12.5%, 3% per year) who were ANA positive. ANA positivity was associated with the composite endpoint occurrence (odds ratio [OR] = 2.84, 95% confidence interval [CI] 1.21-6.65). Furthermore, the presence of both ANA and ACR/EULAR-aPL positivity significantly increased the likelihood of the composite endpoint (OR = 4.85, 95%CI 1.75-13.43).
conclusionsPositive ANA coexisting with ACR/EULAR-aPL may contribute to the failure of oral anticoagulation in AF patients, highlighting a potential role of autoimmune mechanisms in thromboembolism associated with this common arrhythmia. Key Points • The role of antinuclear antibodies (ANA) in atrial fibrillation (AF) remains underexplored, despite their known association all-cause mortality. • This study addresses the gap by evaluating coexistence of ANA and antiphospholipid antibodies in accordance to ACR/EULAR (ACR/EULAR-aPL) in anticoagulated AF patients without autoimmune disease. • ANA positivity, particularly when coexisting with ACR/EULAR-aPL, was associated with an increased risk of thromboembolic events despite anticoagulation. • ANA was more frequently detected in patients who experienced the composite endpoint of ischaemic stroke, transient ischaemic attack, or cardiovascular death.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.